What is the current size of the smart insulin pens & pumps market?

The market size of smart insulin pens & pumps in 2027 is calculated to be USD 9.24 billion.

How much is the smart insulin pens & pumps industry expected to grow by 2036?

Smart Insulin Pens & Pumps Market size was more than USD 8.66 billion in 2026 and is set to grow at a 7.98% CAGR between 2027 and 2036, exceeding USD 18.66 billion by 2036.

How is digital health integration changing demand for smart insulin delivery systems?

Connected glucose monitoring and remote care workflows are encouraging adoption of insulin devices that provide dosing visibility, enable personalized management, and improve coordination between patients and clinicians.

Which device advancements are strengthening adoption of smart insulin pens and pumps?

Improvements in wearable formats, automated controls, and delivery accuracy are increasing preference for systems that improve convenience, adherence, and consistency in long-term insulin management.

Why do smart insulin pumps lead the smart insulin pens & pumps market?

Smart insulin pumps accounted for 61.53% of the market in 2026, supported by their role in continuous insulin delivery, treatment precision, automated dosing support, and integration into comprehensive diabetes management routines.

Why is homecare the fastest-growing end-use segment in the smart insulin pens & pumps market?

Homecare is growing fastest as patients increasingly manage diabetes independently using connected devices. Convenience, continuous monitoring, and improved support for day-to-day insulin management are accelerating adoption outside clinical settings.

Why does Europe hold the largest share of the smart insulin pens and pumps market?

Europe captured 33.81% of the market in 2026, supported by established diabetes care infrastructure, broad technology access, mature reimbursement systems, and widespread clinical adoption of connected insulin management.

What factors are accelerating market growth in Asia Pacific?

Asia Pacific is projected to grow at a 9.49% CAGR, driven by rising diabetes incidence, expanding digital health adoption, greater healthcare investment, and increasing availability of advanced insulin delivery devices.

Who are the leading players in the smart insulin pens & pumps landscape?

Key companies in the smart insulin pens & pumps market include Novo Nordisk A/S (Denmark), Sanofi S.A. (France), Medtronic plc (Ireland), Insulet Corporation (United States), Tandem Diabetes Care, Inc. (United States), Abbott Laboratories (United States), F. Hoffmann-La Roche AG (Switzerland), Ypsomed AG (Switzerland), SOOIL Development Co., Ltd. (South Korea), Emperra GmbH E-Health Technologies (Germany).